Loading
YM
Y-mAbs Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by WG Biotech ApS, was filed 12 Dec 2023.
Y-mAbs Therapeutics, Inc.: what insiders have been doing
This page follows insider dealings at Y-mAbs Therapeutics, Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. The past year has been quiet: not a single insider filing for Y-mAbs Therapeutics, Inc. The previous disclosure was published on 19 September 2025.
The full history, which starts in 2018, counts 17 purchases against 185 sales.
Elsewhere in the same sector, our signals recently picked up insider purchases at Dynavox Group AB and EssilorLuxottica. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
322
Thresholds
n/a
Buy Volume
€18M
17 ops. · all time
Sell Volume
€78M
185 ops. · all time
Who traded when
BuySaleMichael J. Rossi1 sale
Thomas Gad1 sale
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2024FY ended December 2024 · cache
Income statement
RevenueUS$75.5M
Gross profitUS$62.6M83% margin
Net income-US$25.5M-33.8% margin
Last declaration on 19 September 2025
Declarations322 total
25,080 sharesCommon StockSEC:0001751804-25-000004:1
5,825 shares@ US$8.60100.0% of flowCommon StockSEC:0001751804-25-000004:0
25,080 sharesCommon StockSEC:0001752467-25-000005:1
25,080 sharesCommon StockSEC:0001245624-25-000004:1
4,559,233 shares@ US$8.6066.4% of flowCommon StockSEC:0001753185-25-000004:2
60,235 sharesCommon StockSEC:0001753224-25-000004:1
25,080 sharesCommon StockSEC:0001106519-25-000005:1
129,101 sharesCommon StockSEC:0001948795-25-000004:1
39,301 sharesCommon StockSEC:0001753231-25-000004:1
25,080 sharesCommon StockSEC:0001753185-25-000004:1
67,681 shares@ US$8.601.1% of flowCommon StockSEC:0001753224-25-000004:2
60,000 shares@ US$8.601.0% of flowCommon StockSEC:0001753224-25-000004:3
2,194,278 shares@ US$8.6062.3% of flowCommon StockSEC:0001245624-25-000004:2
5,825 shares@ US$8.600.6% of flowCommon StockSEC:0001753185-25-000004:0
4,559,233 shares@ US$8.6083.6% of flowCommon StockSEC:0001753193-25-000004:0
21,500 sharesCommon StockSEC:0001732197-25-000005:0
77,800 sharesCommon StockSEC:0001585839-25-000004:0
7,982 shares@ US$8.6075.4% of flowCommon StockSEC:0001948795-25-000004:0
12,799 shares@ US$8.6058.5% of flowCommon StockSEC:0001753231-25-000004:0
245,486 shares@ US$8.6017.2% of flowCommon StockSEC:0001753224-25-000004:0
5,825 shares@ US$8.60100.0% of flowCommon StockSEC:0001752467-25-000005:0
31,603 shares@ US$8.60100.0% of flowCommon StockSEC:0001245624-25-000004:0
5,825 shares@ US$8.60100.0% of flowCommon StockSEC:0001106519-25-000005:0
25,080 shares0Common StockSEC:0001415889-25-019050:0
25,080 shares0Common StockSEC:0001415889-25-019049:0
25 of 322 declarations
About Y-mAbs Therapeutics, Inc.
Y-mAbs Therapeutics, Inc. is a U.S.-listed biopharmaceutical company traded on Nasdaq (within the broader NYSE/NASDAQ U.S. listed equity universe), headquartered in Princeton, New Jersey, United States. The company has been built around rare oncology and targeted biologics, combining a commercial product platform with an R&D engine focused on monoclonal antibodies and radiopharmaceutical innovation. Founded in 2015, Y-mAbs initially emerged as a developer of targeted therapies for rare pediatric cancers and later expanded its strategic scope toward next-generation pretargeted radioimmunotherapy.
Its core commercial asset is DANYELZA® (naxitamab-gqgk), a GD2-directed monoclonal antibody approved by the FDA for certain patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow after prior therapy. DANYELZA is the company’s lead revenue-generating product and the foundation of its transition from a pure development-stage biotech into a commercial-stage oncology company. The product has been rolled out across multiple treatment centers in the United States, and Y-mAbs also reports activity outside the U.S. through localized access and commercial programs. Alongside DANYELZA, the company is advancing its SADA PRIT platform (Self-Assembly DisAssembly Pretargeted Radioimmunotherapy), designed to improve dose delivery for radiolabeled cancer treatment while limiting off-target radiation exposure. Y-mAbs also uses its Y-BiClone platform to generate bispecific antibody candidates.
Read moreShow less
From a competitive standpoint, Y-mAbs occupies a specialized niche in rare and difficult-to-treat cancers, where scientific differentiation, regulatory barriers, and unmet medical need can create meaningful value if clinical and commercial execution succeeds. The company’s positioning is supported by an FDA-approved asset, an orphan-oncology profile, and a pipeline that targets high-value hematology and solid-tumor opportunities, including relapsed/refractory non-Hodgkin lymphoma, sarcomas, and adult neuroblastoma. Geographically, the business remains centered on the United States for commercial execution, while international expansion has been pursued through ex-U.S. revenue streams and broader commercialization initiatives.
Recent developments underline a strategic transition. In 2025, Y-mAbs reorganized into two business units, “DANYELZA” and “Radiopharmaceuticals,” making the reporting structure more explicit and highlighting the company’s dual focus on monetizing its approved product and investing in pipeline innovation. The company also reported NCCN guideline support for DANYELZA in high-risk neuroblastoma and initiated a Phase 1 study of CD38-SADA in relapsed/refractory non-Hodgkin lymphoma. Most importantly, Y-mAbs entered into and completed a sale to SERB Pharmaceuticals in 2025, with an all-cash transaction intended to take the company off Nasdaq and crystallize shareholder value. That transaction reinforces the strategic importance of DANYELZA and the broader radiopharmaceutical platform.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
